 |
Parkinsons News: 273 headlines |
|
|||||
Celebrity Fight Night Video  |
||||||||
|
||||||||
|
||||||||
| Sources used by our Parkinsons News Channel Research Team: | ||||||||
| The New York Times, CNN, FOX, CBS, BBC, Mayo Clinic, Johns Hopkins Medicine, UCLA Medical Center, National Institute of Health, Stanford Hospital, Memorial Sloan- Kettering, Yale Cancer Center, Massachusetts General Hospital, Brigham and Women's Hospital, University of Michigan, M. D. Anderson Cancer Center, National Institute of Health, American Cancer Association, NBC, Reuters News, American College of Cardiology, Journal of the American Medical Association & 100's more | ||||||||
| Links | ||||||||
| Barrow Neurological Institute | ||||||||
| Archives |
Thursday
Rotigotine for the treatment of Parkinson's disease...abstract/Entrez PubMed
[Movement Disorders Program, Department of Neurology, Medical College of Georgia,1429 Harper Street, HF-1121 Augusta, GA 30912, USA]
This paper reviews results from preclinical and clinical trials of the new agent, rotigotine, in the treatment of patients with early-stage Parkinson's disease as well as in adjunctive therapy with levodopa for patients with advanced Parkinson's disease, and outlines the potential benefits of rotigotine's unique formulation as a transdermal patch delivery system that allows for continuous, once-daily administration.
Dopaminergic therapies, including levodopa and dopamine agonists, are the mainstays of therapy in Parkinson's disease. With the exception of the injectable short-acting dopamine agonist apomorphine, there is no other widely available non-oral dopaminergic therapy. Rotigotine is a lipid-soluble, non-ergot, D3, D2, D1 dopamine receptor agonist that has demonstrated efficacy as an alternative therapeutic option in both early and advanced Parkinson's disease. More importantly, it is uniquely formulated as a transdermal patch delivery system allowing for continuous, once-daily administration and better patient compliance. Preclinical and clinical trials have shown rotigotine to be a well-tolerated and effective treatment for early-stage Parkinson's disease. Rotigotine has also shown promise as adjunctive therapy with levodopa for the treatment of advanced Parkinson's disease.
[Movement Disorders Program, Department of Neurology, Medical College of Georgia,1429 Harper Street, HF-1121 Augusta, GA 30912, USA]
This paper reviews results from preclinical and clinical trials of the new agent, rotigotine, in the treatment of patients with early-stage Parkinson's disease as well as in adjunctive therapy with levodopa for patients with advanced Parkinson's disease, and outlines the potential benefits of rotigotine's unique formulation as a transdermal patch delivery system that allows for continuous, once-daily administration.
Dopaminergic therapies, including levodopa and dopamine agonists, are the mainstays of therapy in Parkinson's disease. With the exception of the injectable short-acting dopamine agonist apomorphine, there is no other widely available non-oral dopaminergic therapy. Rotigotine is a lipid-soluble, non-ergot, D3, D2, D1 dopamine receptor agonist that has demonstrated efficacy as an alternative therapeutic option in both early and advanced Parkinson's disease. More importantly, it is uniquely formulated as a transdermal patch delivery system allowing for continuous, once-daily administration and better patient compliance. Preclinical and clinical trials have shown rotigotine to be a well-tolerated and effective treatment for early-stage Parkinson's disease. Rotigotine has also shown promise as adjunctive therapy with levodopa for the treatment of advanced Parkinson's disease.